Q5157 Injection, denosumab-bmwo, 1 milligrams
Also known as: denosumab biosimilar, RANKL inhibitor, bone therapy
Injection of denosumab-bmwo (Mifepristone), a biosimilar to denosumab, administered at 1 milligram per dose.
In Plain Language
bone strengthening injection; osteoporosis treatment; bone loss prevention
Clinical Context
Used for prevention of skeletal complications in patients with bone metastases or advanced malignancy. Administered subcutaneously every 4 weeks.
RVU Information
CPT Q5157 does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
Q-codes are temporary HCPCS codes used when no permanent code exists. Coverage and reimbursement vary by payer and region. Document the clinical indication and medical necessity. These codes may be replaced by permanent codes in future HCPCS updates.
Specialties
Frequently Asked Questions
What is CPT code Q5157?
CPT Q5157 (Injection, denosumab-bmwo, 1 milligrams) is a Q Codes code. Injection of denosumab-bmwo (Mifepristone), a biosimilar to denosumab, administered at 1 milligram per dose.
Is Q5157 covered by insurance?
Q5157 is a temporary HCPCS code. Coverage varies by payer and may change when permanent codes are assigned. Used for prevention of skeletal complications in patients with bone metastases or advanced malignancy. Administered subcutaneously every 4 weeks.
When is CPT Q5157 used?
Used for prevention of skeletal complications in patients with bone metastases or advanced malignancy. Administered subcutaneously every 4 weeks.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.